Koma Holdings invests 3.5 trillion KRW to acquire Youzheng Biotech... Announces innovative domestic clinical trials

TechubNews · 2026-03-05T00:10:25+00:00

Koma Holdings acquires the operating rights of Yuzheng Biological and becomes its largest shareholder. The two parties signed an agreement to improve the financial structure. This strategic partnership aims to promote high-end non-clinical service businesses and is expected to bring positive impacts to both companies and the entire industry.

TechubNews

2026-03-05 00:10:25

Abstract generation in progress

Koma Holdings acquires the operational rights of Yu Zheng Bio, with a rising expectation of a new merger in the domestic clinical trial outsourcing sector. The acquisition was carried out through Koma Holdings becoming the largest shareholder by issuing convertible bonds worth 35 billion Korean won.

Through this agreement with Koma Holdings, Yu Zheng Bio has set goals to improve its financial structure. If all convertible bonds are converted into common stock, Koma Holdings will become the largest shareholder of Yu Zheng Bio. Before conversion, both parties have agreed that Koma Holdings will exercise voting rights as a trustee. This move signifies a dramatic change in the existing management system.

This leap was a rapid decision following the death of Yu Zheng Bio founder Chairman Qian Bingnian and the appointment of his eldest daughter, Qian Xizheng, as a director. The actual transfer of operational control is expected to occur within approximately 10 months. The company explained that choosing Koma Holdings as a strategic partner aims to advance high-end non-clinical services and ensure stable funding. This decision was based on a high level of mutual understanding of the business and shared growth strategies.

Koma Holdings’ acquisition is expected to have a positive impact on both companies. In particular, Koma Holdings will be able to integrate Yu Zheng Bio’s scientific capabilities and potentially gain additional growth momentum in the medium to long term. This change could not only strengthen the market positions of both companies but also inject vitality into the entire industry.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.